

Maklumat tambahan indikasi untuk upload pada laman web  
Year 2016

Products Approved For Additional Indication (DCA 306 – 25 November 2016)

NO	PRODUCT (ACTIVE INGREDIENT)	ADDITIONAL INDICATION	MARKETING AUTHORIZATION HOLDER
1.	1.1 <b>Afinitor 2.5 mg Tablet</b> [Everolimus 2.5mg]  1.2 <b>Afinitor 5 mg Tablet</b> [Everolimus 5mg]  1.3 <b>Afinitor 10 mg Tablet</b> [Everolimus 10mg]	➤ Indication:  <i>Afinitor is indicated for the treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy.</i>	<b>NOVARTIS CORPORATION (MALAYSIA) SDN. BHD.</b> Level 22, Tower B, Plaza 33 No. 1, Jalan Kemajuan, Seksyen 13 46200 Petaling Jaya, Selangor